[{"orgOrder":0,"company":"Adhera Therapeutics","sponsor":"Melior Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tolimidone","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adhera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adhera Therapeutics \/ Melior Pharmaceuticals I","highestDevelopmentStatusID":"6","companyTruncated":"Adhera Therapeutics \/ Melior Pharmaceuticals I"},{"orgOrder":0,"company":"Adhera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Armesocarb","moa":"Dopamine reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"Adhera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adhera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adhera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Adhera Therapeutics","sponsor":"Biodexa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Tolimidone","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adhera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adhera Therapeutics \/ Biodexa Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Adhera Therapeutics \/ Biodexa Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Adhera Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Under the agreement, Biodexa gain rights to develop and commercialize MLR-1023 (tolimidone), a selective activator of the enzyme lyn kinase and Phase II Ready Asset for Type 1 Diabetes.

                          Brand Name : MLR-1023

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 27, 2023

                          Lead Product(s) : Tolimidone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Biodexa Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : MLR-1019 (armesocarb) is is the active enantiomer in mesocarb, a new class of drug for Parkinson’s Disease (PD) and represents the only drug to address both movement and non-movement symptoms of PD.

                          Brand Name : MLR-1019

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 15, 2021

                          Lead Product(s) : Armesocarb

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Adhera will license MLR-1023 (tolimidone) from Melior Pharma 1 for the purpose of developing a novel therapeutic for Type 1 diabetes. MLR-1023, a lyn kinase activator, which has shown exceptional clinical safety and tolerability in Phase 2a and Phase 2b ...

                          Brand Name : MLR-102

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 24, 2021

                          Lead Product(s) : Tolimidone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Melior Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank